Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. GNFTF.PINK

Genfit SA (GNFTF PINK) stock market data APIs

$5.53 0(0%) as of July 25, 2024
Price chart is built with Anychart

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

Genfit SA Financial Data Overview

5.53
5.53
-
5.53
5.53
2.95-5.53
274 M
49 861 K
34 483 K
1.065
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'GNFTF',
Type: 'Common Stock',
Name: 'Genfit SA',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000R2VX62',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Genfit SA Fundamental Data is available in our Financial Data APIs

  • Net Revenue 34 483 K
  • EBITDA -29 268 000
  • Earnings Per Share -0.63
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Genfit SA Earnings via APIs

  • Latest Release 2024-04-04
  • EPS/Forecast 1.35

Get Genfit SA End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Genfit SA latest news via APIs

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GENFIT S.A. Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland)July12, 2023– GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to impro...

Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients

Ipsen SA (OTC: IPSEY) and Genfit SA (NASDAQ: GNFT) announced topline data from the Phase 3 ELATIVE trial evaluating the efficacy and safety of elafibranor for primary biliary cholangitis (PBC) who hav...
Do you have any questions?
support@eodhistoricaldata.com